Sun Pharma, the world’s fifth-largest generics maker, has become the latest in a string of Indian drug companies to ramp up its interest in the OTC sector as it seeks to buffer its revenue stream from regulatory uncertainties and currency volatility.

Sun Pharma, the world’s fifth-largest generics maker, has become the latest in a string of Indian drug companies to ramp up its interest in the OTC sector as it seeks to buffer its revenue stream from regulatory uncertainties and currency volatility.

Indian generics giant Dr. Reddy’s has made its first foray into the $40bn branded US consumer health goods market, buying half a dozen over-the-counter (OTC) labels, including well-known names like painkiller Bufferin, from Ducere.

Indian generics giant Dr. Reddy’s has made its first foray into the $40bn branded US consumer health goods market, buying half a dozen over-the-counter (OTC) labels, including well-known names like painkiller Bufferin, from Ducere.